TrialBritish journal of haematology2021

Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.

Ceri Bygrave et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.